An open-label single-centre pilot study to evaluate the safety and tolerability of PPS in subjects with MPS ILikeFollowShareSource: Bratkovic, D. et alNovember 23, 2021Share your feedbackQuestions (0)Post questionYour question will be sent privately to Paradigm Biopharmaceuticals. The company may choose to make this question public.Start the conversationAsk Paradigm Biopharmaceuticals a question about this update.Discover
